SANOFI-AVENTIS Form 6-K February 12, 2008

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of February 2008

Commission File Number: 001-31368

SANOFI-AVENTIS

(Translation of registrant s name into English)

174, avenue de France, 75013 Paris, FRANCE

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

For	rm 20-F x	Form 40-F "			
Indicate by check mark if the registrant is subm	nitting the Form 6-K	in paper as permitte	ed by Regulation S-T Ru	ıle 101(b)(1):	
Indicate by check mark if the registrant is subm	nitting the Form 6-K	ζ in paper as permitto	ed by Regulation S-T Ru	ale 101(b)(7):	
Indicate by check mark whether the registrant the Commission pursuant to Rule 12g3-2(b) un	, .			reby furnishing the information	tion to
Yes	s	No x			
If Yes marked, indicate below the file numb	er assigned to the re	egistrant in connection	on with Rule 12g3-2(b):	82-	

In February 2008, sanofi-aventis issued the press releases attached hereto as Exhibits 99.1 and 99.2, which are incorporated herein by reference.

Exhibit List

Exhibit No.	<u>Description</u>
Exhibit 99.1	Press release dated February 12, 2008: 2007 Financial Results
Exhibit 99.2	Press release dated February 12, 2008: Sanofi-aventis enters into Antibody Agreements with Dyax for the fully human monoclonal antibody DX-2240 and Phage Display Technology

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: February 12, 2008 SANOFI-AVENTIS

By /S/ Patricia Kodyra

Name: Patricia Kodyra

Title: Associate Vice President,

Corporate Law, Financial and

Securities Law

3

Exhibit Index

Exhibit No.	<u>Description</u>
Exhibit 99.1	Press release dated February 12, 2008: 2007 Financial Results.
Exhibit 99.2	Press release dated February 12, 2008: Sanofi-aventis enters into Antibody Agreements with Dyax for the fully human monoclonal antibody DX-2240 and Phage Display Technology .